Ketamine and Magnesium for Refractory Neuropathic Pain

Posted on by Dr Clemens
Authors: Gisèle Pickering, M.D., Ph.D., D.Pharm. et al
Anesthesiology 7 2020, Vol.133, 154-164.
Background: Ketamine is often used for the management of refractory chronic pain. There is, however, a paucity of trials exploring its analgesic effect several weeks after intravenous administration or in association with magnesium. The authors hypothesized that ketamine in neuropathic pain may provide pain relief and cognitive–emotional benefit versus placebo and that a combination with magnesium may have an additive effect for 5 weeks.Methods: A randomized, double-blind, crossover, placebo-controlled study (NCT02467517) included 20 patients with neuropathic pain. Each ketamine-naïve patient received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulfate (3g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion. Secondary endpoints included pain (at 7, 15, 21 and 28 days) and health-related, emotional, sleep, and quality of life questionnaires.Results: Daily pain intensity was not significantly different between the three groups (n = 20) over 35 days (mean area under the curve = 185 ± 100, 196 ± 92, and 187 ± 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively, P = 0.296). The effect size of the main endpoint was −0.2 (95% CI [−0.6 to 0.3]; P = 0.425) for ketamine versus placebo, 0.2 (95% CI [−0.3 to 0.6]; P = 0.445) for placebo versus ketamine/magnesium and -0.4 (95% CI [−0.8 to 0.1]; P = 0.119) for ketamine versus ketamine/magnesium. There were no significant differences in emotional, sleep, and quality of life measures. During placebo, ketamine, and ketamine/magnesium infusions, 10%, 20%, and 35% of patients respectively reported at least one adverse event.Conclusions: The results of this trial in neuropathic pain refuted the hypothesis that ketamine provided pain relief at 5 weeks and cognitive–emotional benefit versus placebo and that a combination with magnesium had any additional analgesic effect.

Editor’s Perspective:

What We Already Know about This Topic:

  • The use of low-dose ketamine infusion for the treatment of chronic pain has expanded rapidly despite a paucity of data supporting the practice

  • Magnesium ion, like ketamine, is a blocker of N-methyl-d-aspartate receptor function that may have analgesic properties in some settings

What This Article Tells Us That Is New:

  • Using a triple-crossover paradigm, saline, ketamine, and ketamine + magnesium infusions were given to a group of 20 patients with chronic neuropathic pain

  • No effect of either the ketamine or ketamine + magnesium in terms of pain relief over the 35 days after infusions was identified

  • Additional secondary health-related, emotional, sleep, and quality of life measures were also unchanged by the drug infusionsReferences

References 
1. Schwartzman, RJ, Alexander, GM, Grothusen, JR, Paylor, T, Reichenberger, E, Perreault, M . Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study. Pain. 2009; 147:107–15 
2. Sigtermans, MJ, van Hilten, JJ, Bauer, MC, Arbous, MS, Marinus, J, Sarton, EY, Dahan, A . Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009; 145:304–11 
3. Jørum, E, Warncke, T, Stubhaug, A . Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine–a double-blind, cross-over comparison with alfentanil and placebo. Pain. 2003; 101:229–35 
4. Rabben, T, Skjelbred, P, Oye, I . Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther. 1999; 289:1060–6 
5. Mercadante, S, Arcuri, E, Tirelli, W, Casuccio, A . Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000; 20:246–52 
6. Graven-Nielsen, T, Aspegren Kendall, S, Henriksson, KG, Bengtsson, M, Sörensen, J, Johnson, A, Gerdle, B, Arendt-Nielsen, L . Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000; 85:483–91 
7. Kvarnström, A, Karlsten, R, Quiding, H, Gordh, T . The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand. 2004; 48:498–506
8. Cohen, SP, Bhatia, A, Buvanendran, A, Schwenk, ES, Wasan, AD, Hurley, RW, Viscusi, ER, Narouze, S, Davis, FN, Ritchie, EC, Lubenow, TR, Hooten, W . Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018; 43:521–46 
9. Michelet, D, Brasher, C, Horlin, AL, Bellon, M, Julien-Marsollier, F, Vacher, T, Pontone, S, Dahmani, S . Ketamine for chronic non-cancer pain: A meta-analysis and trial sequential analysis of randomized controlled trials. Eur J Pain. 2018; 22:632–46 
10. Pickering, G, Morel, V, Micallef, J . Ketamine and chronic pain: A narrative review of its efficacy and safety. Article in French. Thérapie. 2018; 73:529–39 
11. Amr, Y . Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: A prospective, randomized, double blind trial. Pain Physician. 2010; 13:245–9 
12. Fallon, MT, Wilcock, A, Kelly, CA, Paul, J, Lewsley, LA, Norrie, J, Laird, BJ . Oral ketamine vs placebo in patients with cancer-related neuropathic pain: A randomized clinical trial. JAMA Oncol. 2018; 4:870–2 
13. Lynch, ME, Clark, AJ, Sawynok, J, Sullivan, M . Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: A randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005; 103:140–6 
14. Rigo, FK, Trevisan, G, Godoy, MC, Rossato, MF, Dalmolin, GD, Silva, MA, Menezes, MS, Caumo, W, Ferreira, J . Management of neuropathic chronic pain with methadone combined with ketamine: A randomized, double blind, active-controlled clinical trial. Pain Physician. 2017; 20:207–15
15. Begon, S, Pickering, G, Eschalier, A, Dubray, C . Magnesium increases morphine analgesic effect in different experimental models of pain. Anesthesiology. 2002; 96:627–32 
16. Farsi, L, Naghib Zadeh, M, Afshari, K, Norouzi-Javidan, A, Ghajarzadeh, M, Naghshband, Z, Keshavarz, M . Effects of combining methylprednisolone with magnesium sulfate on neuropathic pain and functional recovery following spinal cord injury in male rats. Acta Med Iran. 2015; 53:149–57 
17. Ulugol, A, Aslantas, A, Ipci, Y, Tuncer, A, Hakan Karadag, C, Dokmeci, I . Combined systemic administration of morphine and magnesium sulfate attenuates pain-related behavior in mononeuropathic rats. Brain Res. 2002; 943:101–4 
18. Crosby, V, Wilcock, A, Corcoran, R . The safety and efficacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. J Pain Symptom Manage. 2000; 19:35–9
19. Mauskop, A, Altura, BT, Cracco, RQ, Altura, B . Intravenous magnesium sulfate relieves cluster headaches in patients with low serum ionized magnesium levels. Headache. 1995; 35:597–600 
20. Pickering, G, Morel, V, Simen, E, Cardot, JM, Moustafa, F, Delage, N, Picard, P, Eschalier, S, Boulliau, S, Dubray, C . Oral magnesium treatment in patients with neuropathic pain: A randomized clinical trial. Magnes Res. 2011; 24:28–35 
21. Jabbour, HJ, Naccache, NM, Jawish, RJ, Abou Zeid, HA, Jabbour, KB, Rabbaa-Khabbaz, LG, Ghanem, IB, Yazbeck, P . Ketamine and magnesium association reduces morphine consumption after scoliosis surgery: Prospective randomised double-blind study. Acta Anaesthesiol Scand. 2014; 58:572–9 
22. Delage, N, Morel, V, Picard, P, Marcaillou, F, Pereira, B, Pickering, G . Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): Study protocol for a randomized controlled trial. Trials. 2017; 18:517 
23. Bouhassira, D, Attal, N, Alchaar, H, Boureau, F, Brochet, B, Bruxelle, J, Cunin, G, Fermanian, J, Ginies, P, Grun-Overdyking, A, Jafari-Schluep, H, Lantéri-Minet, M, Laurent, B, Mick, G, Serrie, A, Valade, D, Vicaut, E . Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005; 114:29–36 
24. Tan, G, Jensen, MP, Thornby, JI, Shanti, B . Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004; 5:133–7 
25. Melzack, R . The McGill pain questionnaire: From description to measurement. Anesthesiology. 2005; 103:199–202 
26. Bouhassira, D, Attal, N, Fermanian, J, Alchaar, H, Gautron, M, Masquelier, E, Rostaing, S, Lanteri-Minet, M, Collin, E, Grisart, J, Boureau, F . Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004; 108:248–57 
27. Zigmond, AS, Snaith, R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67:361–70 
28. Brazier, JE, Harper, R, Jones, NM, O’Cathain, A, Thomas, KJ, Usherwood, T, Westlake, L . Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ. 1992; 305:160–4 
29. Leplège, A, Ecosse, E, Verdier, A, Perneger, T . The French SF-36 Health Survey: Translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol. 1998; 51:1013–23
30. Buysse, DJ, Reynolds, CF3rd, Monk, TH, Berman, SR, Kupfer, D . The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28:193–213 
31. Verbeke, G, Molenberghs, G. Linear Mixed Models for Longitudinal Data. 2000, New York: Springer-Verlag. doi: 10.1007/978-1-4419-0300-6
32. Bell, RFF, Eccleston, C, Kalso, E . Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017; 6:CD003351 
33. Maher, DP, Chen, L, Mao, J . Intravenous ketamine infusions for neuropathic pain management: A promising therapy in need of optimization. Anesth Analg. 2017; 124:661–74 
34. Savic Vujovic, KR, Vuckovic, S, Srebro, D, Medic, B, Stojanovic, R, Vucetic, C, Prostran, M . A synergistic interaction between magnesium sulphate and ketamine on the inhibition of acute nociception in rats. Eur Rev Med Pharmacol Sci. 2015; 19:2503–9 
35. Pouteau, E, Kabir-Ahmadi, M, Noah, L, Mazur, A, Dye, L, Hellhammer, J, Pickering, G, Dubray, C . Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial. PLoS One. 2018; 13:e0208454 
36. Jevtovic-Todorovic, V, Wozniak, DF, Powell, S, Nardi, A, Olney, J . Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects. Brain Res. 1998; 781:202–11
37. Coyle, CM, Laws, K . The use of ketamine as an antidepressant: A systematic review and meta-analysis. Hum Psychopharmacol. 2015; 30:152–63 
38. Zhang, W, Zou, K, Doherty, M . Placebos for knee osteoarthritis: Reaffirmation of “needle is better than pill.”. Ann Intern Med. 2015; 163:392–3 
39. Whiteside, N, Sarmanova, A, Chen, X, Zou, K, Abdullah, N, Doherty, M, Zhang, W . Proportion of contextual effects in the treatment of fibromyalgia: A meta-analysis of randomised controlled trials. Clin Rheumatol. 2018; 37:1375–82 
40. Paul-Savoie, E, Bourgault, P, Potvin, S, Gosselin, E, Lafrenaye, S . The impact of pain invisibility on patient-centered care and empathetic attitude in chronic pain management. Pain Res Manag. 2018; 2018:6375713 
41. McCloud, TL, Caddy, C, Jochim, J, Rendell, JM, Diamond, PR, Shuttleworth, C, Brett, D, Amit, BH, McShane, R, Hamadi, L, Hawton, K, Cipriani, A . Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev Edited by Cochrane Common Mental Disorders Group. 2015; 29:CD011611
42. McGirr, A, Berlim, MT, Bond, DJ, Fleck, MP, Yatham, LN, Lam, R . A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015; 45:693–704
43. Su, TP, Chen, MH, Li, CT, Lin, WC, Hong, CJ, Gueorguieva, R, Tu, PC, Bai, YM, Cheng, CM, Krystal, J . Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017; 42:2482–92 
44. Xu, Y, Hackett, M, Carter, G, Loo, C, Gálvez, V, Glozier, N, Glue, P, Lapidus, K, McGirr, A, Somogyi, AA, Mitchell, PB, Rodgers, A . Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. Int J Neuropsychopharmacol. 2016; 19:1–15
Duncan, WCJr, Ballard, ED, Zarate, C . Ketamine-induced glutamatergic mechanisms of sleep and wakefulness: Insights for developing novel treatments for disturbed sleep and mood. Handb Exp Pharmacol. 2019; 253:337–58 
45. Cheatle, MD, Foster, S, Pinkett, A, Lesneski, M, Qu, D, Dhingra, L . Assessing and managing sleep disturbance in patients with chronic pain. Anesthesiol Clin. 2016; 34:379–93 
46. Orhurhu, V, Orhurhu, MS, Bhatia, A, Cohen, S . Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg. 2019; 129:241–54 
47. Colagiuri, B, Sharpe, L, Scott, A . The blind leading the not-so-blind: A meta-analysis of blinding in pharmacological trials for chronic pain. J Pain. 2019; 20:489–500

Leave a Reply

Your email address will not be published. Required fields are marked *